Good evening :)
Place Order
Add to Watchlist

Syncom Formulations (India) Ltd

SYNCOMF

Syncom Formulations (India) Ltd

SYNCOMF
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,900 cr, stock is ranked 1,154
High RiskStock is 4.39x as volatile as Nifty
19.501.37% (-0.27)
19.501.37% (-0.27)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,900 cr, stock is ranked 1,154
High RiskStock is 4.39x as volatile as Nifty

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹1,900 cr, stock is ranked 1,154
High RiskStock is 4.39x as volatile as Nifty

Key Metrics

No LabelNo LabelPB RatioPB RatioDividend YieldDiv. Yield
57.376.60
Sector PESector PESector PBSector PBSector Div YldSctr Div Yld
50.266.380.53%

Forecast & Ratings

Detailed Forecast 
Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Syncom Formulations (India) Limited is a pharmaceutical company that manufactures and markets over 300 pharmaceutical formulations products. It also exports various commodities such as agro and confectionary products and industrial products.

Get more out of Tickertape, Go Pro!

Customise key metrics, see detailed forecasts, download stock data and more

Forecasts

Price

Revenue

Earnings

Income

Balance Sheet

Cash Flow

Income Statement

Loading...

Financial YearFY 2022FY 2023FY 2024TTM
Total Revenue231.68238.86276.92342.41
Raw Materialssubtract137.23142.07158.64289.91
Power & Fuel Costsubtract4.385.316.13
Employee Costsubtract20.7324.4433.57
Selling & Administrative Expensessubtract29.7127.3131.51
Operating & Other expensessubtract7.595.223.68
Depreciation/Amortizationsubtract3.954.544.725.35
Interest & Other Itemssubtract1.933.404.722.83
Taxes & Other Itemssubtract6.396.508.6311.19
EPS0.230.220.270.35
DPS0.030.000.000.00
Payout ratio0.130.000.000.00

Company Updates

Annual Report and Investor Presentation updates mentioned here are as reported by the company to the exchange

Peers & Comparison

Comparing 3 stocks from 
Health CarePharmaceuticals

Loading...

StockPE RatioPE RatioPB RatioPB RatioDiv. YieldDividend Yield
Syncom Formulations (India) Ltd75.076.60
Sun Pharmaceutical Industries Ltd44.986.420.75%
Cipla Ltd29.134.480.87%
Torrent Pharmaceuticals Ltd64.7115.630.88%

Price Comparison

Compare SYNCOMF with any stock or ETF
Compare SYNCOMF with any stock or ETF
SYNCOMF
Loading...

Shareholdings

Promoter Holdings Trend

Total Promoter Holding

Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding

Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Institutional Holdings Trend

Total Retail Holding

Increasing retail holding can be considered bad as it can reflect that institutions and promoters are selling their stake which is being absorbed by retail investors.

In last 3 months, retail holding in the company has almost stayed constant

Foreign Institutional Holding

Foreign Institutional Holding is quantum of stock held by foreign large-quantities-trading entities. Increasing value indicates growing support and comfort for the stock

In last 3 months, foreign institutional holding of the company has almost stayed constant

Tickertape Separator

Shareholding Pattern

Retail and OthersForeign InstitutionsOther Domestic InstitutionsMutual FundsTotal Promoter Holding50.57%0.00%0.00%0.10%49.33%

Dec 2023

Mar 2024

Jun 2024

Sep 2024

Shareholding History

JunSepDec '23MarJunSep0.00%0.00%0.00%0.08%0.09%0.10%

Mutual Funds Holding Trend

Mutual Fund Holding

Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

Top 1 Mutual Funds holding Syncom Formulations (India) Ltd


Funds (Top 1)Market-cap heldWeight3M holding changePortfolio rank
(3M change)
Bandhan BSE Healthcare Index Fund Direct Plan-Growth

Growth
0.0007%0.07%0.07%81/102 (+2)

Compare 3-month MF holding change on Screener

Insider Trades & Bulk Deals

Loading...

smallcases

Looks like this stock is not in any smallcase yet.

Events

Dividend Trend

No dividend trend available

Dividends

Corp. Actions

Announcements

Legal Orders

Upcoming Dividends

No upcoming dividends are available

Past Dividends

Cash Dividend

Ex DateEx DateSep 9, 2022

Final
Final | Div/Share: ₹0.03

Dividend/Share

0.03

Ex DateEx Date

Sep 9, 2022

Cash Dividend

Ex DateEx DateSep 21, 2017

Final
Final | Div/Share: ₹0.02

Dividend/Share

0.02

Ex DateEx Date

Sep 21, 2017

Cash Dividend

Ex DateEx DateSep 22, 2016

Final
Final | Div/Share: ₹0.02

Dividend/Share

0.02

Ex DateEx Date

Sep 22, 2016

Cash Dividend

Ex DateEx DateSep 16, 2015

Final
Final | Div/Share: ₹0.02

Dividend/Share

0.02

Ex DateEx Date

Sep 16, 2015

Cash Dividend

Ex DateEx DateSep 18, 2014

Final
Final | Div/Share: ₹0.02

Dividend/Share

0.02

Ex DateEx Date

Sep 18, 2014

News & Opinions
Earnings
Syncom Formulations (India) consolidated net profit rises 70.66% in the September 2024 quarter

Net profit of Syncom Formulations (India) rose 70.66% to Rs 11.11 crore in the quarter ended September 2024 as against Rs 6.51 crore during the previous quarter ended September 2023. Sales rose 60.26% to Rs 102.31 crore in the quarter ended September 2024 as against Rs 63.84 crore during the previous quarter ended September 2023. ParticularsQuarter EndedSep. 2024Sep. 2023% Var. Sales102.3163.84 60 OPM %11.8910.03 - PBDT16.159.33 73 PBT14.858.45 76 NP11.116.51 71 Powered by Capital Market - Live

1 week agoCapital Market - Live
Corporate
Syncom Formulations (India) to convene board meeting

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 11 November 2024Powered by Capital Market - Live

2 weeks agoCapital Market - Live
Corporate
Syncom Formulations (India) schedules AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Corporate
Syncom Formulations (India) to hold AGM

Syncom Formulations (India) announced that the Annual General Meeting (AGM) of the company will be held on 30 September 2024.Powered by Capital Market - Live

2 months agoCapital Market - Live
Live Market Update
Nifty slips below 24,200 level; Nifty bank shares buck trend; HDFC Bank drops 2.95%

The main equity indices traded with significant losses in mid-afternoon trade. The Nifty dropped below the 24,200 level after hitting the day's high of 24,359.95 in early trade. Nifty Bank shares declined after jumping for four consecutive trading sessions. At 14:25 IST, the barometer index, the S&P BSE Sensex, was down 638.61 points or 0.80% to 79,012.88. The Nifty 50 index slipped 190.50 points or 0.78% to 24,156.50. In the broader market, the S&P BSE Mid-Cap index declined 0.72% and the S&P BSE Small-Cap index fell 0.71%. The market breadth was weak. On the BSE, 1,509 shares rose and 2,320 shares fell. A total of 132 shares were unchanged. Economy: India's CPI inflation in July 2024 stood at 3.54%, which is the lowest since August 2019, according to official data released on Monday, August 12. In the previous month of June 2024, India's retail inflation had stood at 5.08%. Meanwhile, India's IIP recorded a growth of 4.2% in June 2024. The factory output, measured in terms of the Index of Industrial Production (IIP) witnessed a growth of 4% in June 2023. Buzzing Index: The Nifty Bank index declined 1.22% to 49,961.30 the index increased 1.67% in the past four trading sessions. HDFC Bank (down 2.93%), Bandhan Bank (down 1.79%), Bank of Baroda (down 0.98%), Kotak Mahindra Bank (down 0.83%), State Bank of India (down 0.71%), ICICI Bank (down 0.39%), IndusInd Bank (down 0.26%), IDFC First Bank (down 0.22%), Axis Bank (down 0.09%) and Punjab National Bank (down 0.08%) declined. Numbers to track: The yield on India's 10-year benchmark federal paper was up 1.82% to 7.004 as compared with previous close 6.996. In the foreign exchange market, the rupee edged higher against the dollar. The partially convertible rupee was hovering at 83.9700, compared with its close of 83.9725 during the previous trading session. MCX Gold futures for 5 September 2024 settlement shed 0.17% to Rs 70,232. The US Dollar index (DXY), which tracks the greenback's value against a basket of currencies, was up 0.05% to 103.19. The United States 10-year bond yield advanced 0.33% to 3.923. In the commodities market, Brent crude for October 2024 settlement declined 31 cents or 0.38% to $82.30 a barrel. Stocks In Spotlight: Syncom Formulations (India) shed 0.13% after the company reported 73.4% increase in consolidated net profit to Rs 7.63 crore in Q1 FY25 from Rs 4.40 crore in Q1 FY24. Net sales rose by 45.8% year-over-year (YoY) during the quarter to Rs 87.26 crore. Campus Activewear fell 1.90% after the company's consolidated net profit declined 19.38% to Rs 25.38 crore in Q1 FY25 as compared with Rs 31.48 crore in Q1 FY24. Revenue from operations fell 4.13% YoY to Rs 339.16 crore during the quarter, amidst muted demand scenario driven by general elections.Powered by Capital Market - Live

3 months agoCapital Market - Live
Spotlight
Syncom Formulations gains after Q1 PAT rises over 73% YoY

Net sales rose by 45.8% year-over-year (YoY) during the quarter to Rs 87.26 crore. Total expenditure added up to Rs 76.80 crore, up by 43.9% as compared with the same period last year. This was primarily due to higher raw material costs (up 134.1% YoY), higher employee expenses (up 26.5% YoY) and higher other expenses (up 23.9% YoY). Profit before tax in Q1 FY25 stood at Rs 10.10 crore, up by 65.3% from Rs 6.11 crore recorded in Q1 FY24. Syncom Formulations (India) is engaged in the manufacturing and dealing in pharmaceutical drugs and formulations, and trading of commodities. It manufactures and markets a range of pharmaceutical formulations in various dosage forms, such as tablets, capsules, liquids orals, liquid vials and ampoule injections and dry powder injections, ophthalmic preparations, dry syrups and suspensions, ointments, creams, gel, ORS and jelly. Powered by Capital Market - Live

3 months agoCapital Market - Live
Earnings
Syncom Formulations (India) consolidated net profit rises 73.41% in the June 2024 quarter

Net profit of Syncom Formulations (India) rose 73.41% to Rs 7.63 crore in the quarter ended June 2024 as against Rs 4.40 crore during the previous quarter ended June 2023. Sales rose 45.82% to Rs 87.26 crore in the quarter ended June 2024 as against Rs 59.84 crore during the previous quarter ended June 2023. ParticularsQuarter EndedJun. 2024Jun. 2023% Var. Sales87.2659.84 46 OPM %11.9810.80 - PBDT11.407.21 58 PBT10.106.11 65 NP7.634.40 73 Powered by Capital Market - Live

3 months agoCapital Market - Live
Corporate
Syncom Formulations (India) announces board meeting date

Syncom Formulations (India) will hold a meeting of the Board of Directors of the Company on 12 August 2024.Powered by Capital Market - Live

3 months agoCapital Market - Live